Kejun Hu

First Affiliated Hospital of Anhui Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Shumin Pan

Nanjing Normal University

Huanhuan Qiu

Nanjing Normal University

Wangwang Liu

Nanjing Normal University

Guanglin Xu

Shuguang Hospital

Qi Lv

Nanjing Normal University

Wei Wang

Xi'an Polytechnic University

Jiangming Chen

National University of Defense Technology

Qingfeng Yu

China Pharmaceutical University

Hui Hou

Shanxi Medical University

Haonan Sun

Southwest University

Cooperative Institutions

Nanjing Normal University

Anhui Medical University

First Affiliated Hospital of Anhui Medical University

China Pharmaceutical University

Second Hospital of Anhui Medical University

Peking University

Chinese Academy of Medical Sciences & Peking Union Medical College

Jiangsu University

Chinese Academy of Sciences

National University of Defense Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

EuHD1 protects against inflammatory injury driven by NLRP3 inflammasome

International Immunopharmacology (2023)

Huanhuan Qiu Wei Wang Kejun Hu Wangwang Liu Shumin Pan

Pyroptosis

Proinflammatory cytokine

10.1016/j.intimp.2023.109712

Cite

Citations (4)

Interactive model for predicting the oncological outcome of patients with early-stage huge hepatocellular carcinoma after hepatectomy: a multicenter population-based study

Updates in Surgery (2024)

Zixiang Chen Haonan Sun Pingchuan Ma Jiangming Chen Kejun Hu

Nomogram

10.1007/s13304-024-01766-x

Cite

Citations (0)

Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway

Basic & Clinical Pharmacology & Toxicology (2022)

Yu Liao Kejun Hu Wangwang Liu Wei Wang Huanhuan Qiu

Abstract Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death throughout the world. However, the patients with HCC are insensitive to traditional drugs and lack effective therapeutic drugs. Dysregulation of Hippo‐Yes‐associated protein (YAP) signalling is closely associated with HCC. Bortezomib (BTZ) is mainly used in clinical multiple myeloma. It has recently been confirmed that BTZ could suppress cell proliferation in many different types of cancer. Nevertheless, the precise effects of BTZ on HCC and its possible interactions with the Hippo‐YAP signalling pathway in HCC cells remain largely unknown. In this study, HCC cell lines (HepG2 and Huh7) and nude mice with xenograft tumours were used to evaluate the influences of BTZ. Furthermore, we focused on exploring whether BTZ exerts its anti‐HCC effect through the Hippo‐YAP signalling pathway and aimed to lay a theoretical foundation for BTZ as a potential therapeutic drug for HCC. Herein, our results disclose a new mechanism of BTZ in controlling the cell growth of HCC. BTZ downregulates the level of YAP by promoting LATS1 expression to inhibit the growth of HCC cells, which leads to the phosphorylation of YAP and limits YAP nuclear translocation. In sum, our data confirmed that the Hippo‐YAP signalling pathway mediates the anti‐HCC effects of BTZ.

Hippo signaling pathway

10.1111/bcpt.13832

Cite

Citations (2)